Nature Reviews Rheumatology

Papers
(The H4-Index of Nature Reviews Rheumatology is 57. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)
ArticleCitations
Inflammatory arthritis affects men’s fertility525
SLC26A2 deficiency, matrix stiffness and mechanotransduction linked in osteoporosis401
Polygenic risk scores outperform other tests in AS342
Bimekizumab effective across the axSpA spectrum314
No benefit from adding MTX to ustekinumab275
Targeting articular Mmp13 in OA255
Low-dose rituximab can go even lower248
Genome-wide mutagenesis reported in systemic sclerosis227
Rheumatic diseases on the rise209
Osteoarthritis risk factors differ between sexes205
A role for TGFβ and EBV in MIS-C pathogenesis175
Biological and clinical roles of IL-18 in inflammatory diseases166
COVID-19 in people with rheumatic diseases: risks, outcomes, treatment considerations160
New drug formulation reduces bone loss159
Ageing stem cells hold the key to age-related bone degeneration156
FOXP3 splice variant is associated with autoimmune disease144
Towards better management of sterile bone inflammation141
Use of platelet-rich plasma for knee OA not supported by RCT results140
Which NSAIDs are best for OA treatment?132
Down syndrome: insights into autoimmune mechanisms125
Inflammation across tissues: can shared cell biology help design smarter trials?119
MIS-C: myths have been debunked, but mysteries remain110
Urchin-like nanoparticles for miRNA therapy of OA103
2021 ACR guideline for JIA reflects changes in practice101
The value of comparative efficacy studies in informing rheumatology guidelines100
The 2022 ACR vaccination guideline: a call-to-action100
Imbalance of threat and soothing systems in fibromyalgia: rephrasing an established mechanistic model?95
To choose or not? The value of discrete-choice experiments in rheumatology94
Appraising the evolving landscape of protease inhibition in osteoarthritis93
Efficacy and safety of JAK inhibitors in rheumatoid arthritis: update for the practising clinician92
Co-trimoxazole reduces mortality in anti-MDA5-DM91
Low-dose glucocorticoids benefit seniors with RA89
Rheumatology in the digital health era: status quo and quo vadis?84
Fumarate drives interferon release in systemic sclerosis monocytes82
S100A4 inhibition targets fibrosis in SSc81
Sexual dimorphism in the prevalence, manifestation and outcomes of axial spondyloarthritis80
Wnt-induced IGF1 drives OA76
Calprotectin tracks tocilizumab-treated RA76
Biologics in rheumatoid arthritis: a lifetime treatment or possibility of drug holidays?75
Author Correction: Proposals for the rheumatological use of JAK inhibitors74
Publisher Correction: Efficacy and safety of JAK inhibitors in rheumatoid arthritis: update for the practising clinician74
Guiding ILD management in systemic autoimmune rheumatic diseases73
Rheumatic diseases and metabolism: where centre and periphery meet73
A direct link between SARS-CoV-2 and bone loss71
Low back pain is a growing concern69
sCD13 role in arthritis mediated via bradykinin receptor68
Distinct mucosal endotypes as initiators and drivers of rheumatoid arthritis68
Antibiotics keep rheumatic heart disease at bay68
Targeting the IVD clock to halt degeneration65
Insights into IVDD pathogenesis in 202464
Erosive cargo from synovial fibroblasts63
Which DMARD for ICI-associated arthritis?62
PGE2 receptor antagonist has potential to treat osteoarthritis60
Molecular mechanisms of phenotypic variability in monogenic autoinflammatory diseases58
Macrophage-coated nanocarriers for gouty arthritis58
ERAP1 and the return of the UPR in ankylosing spondylitis58
Publisher Correction: Recent advances in the diagnosis and management of neuropsychiatric lupus58
A path towards personalized medicine for autoinflammatory and related diseases57
Chimeric receptors broaden the therapeutic landscape for autoimmune disease57
0.15052485466003